Indication name: Congenital atransferrinemia
Congenital atransferrinemia –
Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report
– 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom,
Italy, Japan & China)
Congenital atransferrinemia is a
very rare hematologic disease caused by a transferrin (TF) deficiency and
characterized by microcytic, hypochromic anemia (manifesting with pallor,
fatigue and growth retardation) and iron overload, and that can be fatal if
left untreated. Transferrinemia / hypotransferrinemia is principally caused by
mutations of the transferrin (TF) gene. the transferrin (TF) gene is located at
band 21 on the long arm (q) of chromosome 3 (3q21).
Competitive landscape of Congenital atransferrinemia includes country specific
approved as well as pipeline therapies. Any asset/ product specific designation
or review and Accelerated Approval are being tracked and supplemented with
analyst commentary.
KOLs insights of Congenital atransferrinemia across 8 MM market from center of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm and Unmet needs.
Congenital atransferrinemia Market Forecast: Patient Based Forecast
Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing,
Market Event and Product Event, Country specific Forecast Model, Market uptake
and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden
and pricing scenario, Summary and Insights.
No comments:
Post a Comment